• Maze Therapeutics CEO Jason V. Coloma disclosed sales of 32,564 common shares at about USD 26 per share on May 22 and May 26.
• The shares were sold from trusts in which Coloma reports indirect beneficial ownership.
• Holdings reported after the sales were 350,987 shares in the Coloma Family Trust and 28,523 shares in The Coloma 2021 Irrevocable Trust.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001676170-26-000007), on May 27, 2026, and is solely responsible for the information contained therein.